IDEF Educational Series VTAMA tapinarof cream, 1% as a Novel Topical Therapy for Adult Plaque Psori

Описание: Join us for our next International Dermatology Foundation Educational Series Webinar: VTAMA (tapinarof) cream, 1% as a Novel Topical Therapy for Adult Plaque Psoriasis.

Take a deep dive into the VTAMA (tapinarof) cream data and learn more about this once-daily, steroid-free option for your adult plaque psoriasis patients.

Important Safety Information
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

----------------------------------

Moderator:

Leon Kircik, MD, FAAD
President, International Dermatology Education Foundation
Clinical Professor of Dermatology
Icahn School of Medicine at Mount Sinai, New York, NY
Indiana University Medical Center, Indianapolis, IN
Medical Director
Physicians Skin Care, PLLC, Louisville, KY
DermResearch, PLLC, Louisville, KY
Skin Sciences, PLLC, Louisville, KY


Speakers:

Mona Shahriari, MD
Assistant Clinical Professor of Dermatology,
Yale University School of Medicine
Associate Director of Clinical Trials,
CCD Research
Senior Editor,
Journal of Psoriasis and Psoriatic Arthritis
Central Connecticut Dermatology